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CONDUCTING PHARMACOECONOMIC 
RESEARCH IN THE ABSENCE OF
COUNTRY-SPECIFIC DATA
Miller B1, Rosner AJ2, Becker DL2
1Pharmacia Canada, Mississauga, ON, Canada; 2Innovus 
Research Inc, Burlington, ON, Canada
In an ideal world, appropriate pharmacoeconomic evi-
dence would be collected to meet the needs of the local
reimbursement environment. Unfortunately, due to clini-
cal research limitations and time constraints, we are often
faced with a lack of the necessary data. OBJECTIVE: Us-
ing an anti-infective as our case study, we present an ap-
proach that we developed to overcome the challenge of
creating an economic argument for Canadian hospital
setting in the absence of country-specific data. METH-
ODS: Our methodology involved a multi-step approach:
(i) hospital formulary committee members were con-
sulted to identify the submission requirements; (ii) a
panel of experts were surveyed to understand local treat-
ment patterns; (iii) the survey results were used in a case
modeling exercise to determine the applicability of the
randomized clinical trial (RCT) protocol to the Canadian
environment; and (iv) a chart review was undertaken to
validate results of the case modeling exercise. RESULTS:
Hospital formulary committees preferred Canadian-spe-
cific evidence of a new product’s economic value. Com-
mittee members were generally unfamiliar with pharma-
coeconomic concepts and preferred that a complicated
economic model not be used. Results of the expert survey
indicated that there are important differences between
the RCT protocol and Canadian treatment patterns.
These differences include restrictive inclusion/exclusion
criteria, an excess of protocol-driven tests and proce-
dures, and treatment strategies that are not necessarily re-
flective of real-life. The case modeling exercise allowed
for a structured method to hypothesize on the real-world
impact of the product. An ongoing chart review will be
used to confirm these hypotheses. CONCLUSIONS: It is
anticipated that issues surrounding the absence of coun-
try-specific data will continue to plague researchers for
the foreseeable future. Use of this multi-step approach
provides a rigorous method for making conclusions in
the absence of locally acquired evidence.
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CONFIRMATION OF THE DECISION RULES AND 
ASSUMPTIONS FOR A MODEL OF DIABETES 
TREATMENT USING AN EXPERT PANEL
Caro J1, Salas M1, Ward A1, Sung J2, Shah A2
1Caro Research Institute, Concord, MA, USA; 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVE: To assess systematically, using a panel of
physician experts, the assumptions made for a pharmaco-
economic model regarding the indications, treatment ini-
tiation and decision rules for management of type 2 dia-
betics. METHODS: The panel consisted of 7 physicians
(three family physicians, two internists and two endocri-
nologists) who were randomly selected from a pool of
high-volume prescribers. The panel was contacted by
phone and upon acceptance, they were mailed a 63-item
questionnaire cover clinical criteria for treatment man-
agement, adherence to diabetes guidelines, decision rules
for failure treatment, resource use and tests requested for
drug-naïve and previously treated patients. The question-
naire was developed based on literature review and pilot-
tested between two clinicians for appropriateness. The
ratings were done using a 5-item Likert scale ranging
from “strongly agree” to “strongly disagree”. RESULTS:
All participating physicians completed the questionnaire.
Endocrinologists and internists follow the American Dia-
betes Association guidelines (ADA). Only two family
physicians use the ADA guidelines. The main assump-
tions for the pharmacoeconomic model coincided with
the experts’ opinion, such as the initial treatment for a
drug-naïve type 2 diabetic patient is monotherapy and af-
ter its failure an increased dose followed by addition of
another treatment is recommended. Treatment adjust-
ment is based on glycosylated hemoglobin, post-prandial
glucose or fasting plasma glucose. For any treatment
changes, patient should visit physician office but they are
not usually hospitalized. The presence of side effects is an
indication to decrease the dose. Number and type of lab-
oratory tests are independent of drug-naïve status. There
are no differences in the criteria used for treatment selec-
tion and treatment changes between drug-naïve patients
and previously treated patients. Furthermore experts do
not recommend switching medications. CONCLUSIONS:
An expert panel is a useful tool to assess model assump-
tions.
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OBJECTIVES: When comparing patient management
and patient outcomes, the available services within a
catchment area appear to be a major confounding factor.
The ESMS aims to classify services and measure their ac-
tivity in a standardized way, which opens new opportuni-
ties to adjust for service offer. The ESMS allows to map
the services available in a set of catchment areas and to
identify different profiles. In addition we evaluate the ac-
curacy of the French standardized classification of mental
health services and the applicability of the instrument in
France. METHODS: 171 services in 24 catchment areas
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were involved in the study, which focused on the French
public mental health care system. Each service was classi-
fied according to the ESMS and data were collected on
service use. The data for each catchment area were aggre-
gated in residential use, structured day activities, continu-
ous out patient care and emergency out patient care, then
a cluster analysis was performed. The ESMS classifica-
tion of the services based on function was compared to
the official French description of services. RESULTS:
Four classes were identified: Class 1 high activity in all
services, class 2 low activity in all services, class 3 low ac-
tivity in continuous ambulatory care, class 4 high activity
in continuous ambulatory care. The ESMS confirmed the
consistency between the French official description of the
services’ missions and the actual activity. 10% of the ser-
vices had at least one additional “non official” function.
The study showed that the ESMS was adapted for use in
France, but it requires expert supervision for large-scale
implementation. CONCLUSIONS: The ESMS proves to
be useful not only in mental health service research, but
can also bring the possibility to adjust for the catchment
area’s service profile in outcomes research.
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THE AVANDIA WORLDWIDE AWARENESS 
REGISTRY (AWARE®): AN INTERNET-BASED 
PROGRAM FOR EVALUATION OF CLINICAL, 
HUMANISTIC AND ECONOMIC OUTCOMES OF 
PATIENTS WITH TYPE 2 DIABETES
Bakst A1, Meletiche DM1, Arnold R2, Harjono H2, Najib M2, 
Cobitz A1
1GlaxoSmithKline, Collegeville, PA, USA; 2Pharmacon 
International, Inc, New York, NY, USA
AWARe® is an Internet-based database designed to cap-
ture clinical and humanistic outcomes from diabetes
practice settings around the world. The main goal of
AWARe® is to better understand how patients with type
2 diabetes respond to different treatments in a naturalis-
tic environment. OBJECTIVE: To describe an innovative
method of collecting clinical, humanistic and economic
outcomes of patients with type 2 diabetes in a “real
world” practice setting. METHODS: The data collection
methods involve the electronic linkage of clinical infor-
mation and humanistic outcomes of patients with type 2
diabetes. Patients at least 18 years of age who are main-
tained on oral antidiabetic therapy are eligible to partici-
pate in AWARe®. As providers enter patients’ clinical in-
formation into the patient’s electronic medical record, the
data elements of interest are automatically transmitted to
a secure Internet site (Pharmacon EB-HealthTM) where the
data are stored and continuously updated. Data collected
in AWARe® include: demographic information, pre-
scription use, HbA1c, fasting plasma glucose, total cho-
lesterol, triglycerides, LDL, HDL, blood pressure, liver
function tests, the SF-36, and the Diabetes and Treatment
Satisfaction Questionnaire (DTSQ). Every six months,
participants use hand-held devices to complete the elec-
tronic versions of the SF-36 and the DTSQ. The results
from these surveys are instantaneously transmitted via
wireless technology to EB-HealthTM. CONCLUSION:
AWARe® permits immediate retrieval of clinical and hu-
manistic information from an Internet-based registry. In-
formation on the patient’s clinical progress may be con-
tinuously transmitted to EB-HealthTM, allowing researchers,
clinicians and administrators to perform “real time”
analyses of the clinical effectiveness of antidiabetic ther-
apy, as well as to determine its impact on patients’ qual-
ity of life and satisfaction with treatment. As AWARe® is
expanded to sites around the US and throughout the
world, it will provide valuable information on the impact
of the different treatments for type 2 diabetes on patients’
clinical, humanistic and economic outcomes.
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METHODOLOGICAL COMPLEXITIES IN USING 
ADMINISTRATIVE CLAIMS DATABASES TO 
EVALUATE QUALITY OF CARE FOR 
ATTENTION-DEFICIT/HYPERACTIVITY 
DISORDER
Hankin CS1, Wright AT2
1ALZA Corporation, Mountain View, CA, USA; 2Advance PCS, 
Hunt Valley, MD, USA
OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is one of the most prevalent of childhood men-
tal disorders, and represents the most common reason
children are referred to mental health providers.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who use large-scale administrative databases to evalu-
ate quality of care for mental disorders and associated
patient outcomes. Purchasers of health care who provide
health services to patients with psychiatric disorders.
The presence of the disorder is associated with substan-
tial health resource utilization and costs. Although evi-
dence-based guidelines for the pharmacologic treatment
of ADHD are widely available, little is known about vari-
ation in provider prescribing practices, patient compli-
ance, and attendant patient health outcomes. This is espe-
cially problematic because psychostimulants, commonly
prescribed for ADHD as a daily regimen, are frequently
taken solely on an “as needed” basis to improve behav-
iors during school hours. We are currently conducting a
program of research using large-scale, national, inte-
grated pharmacy benefits and medical claims databases
to examine the quality of ADHD pharmacologic care, pa-
tient compliance, and associated patient outcomes. The
objectives of this workshop are to discuss the complexi-
